Press Release

Shilpa Medicare Limited, through its material subsidiary Shilpa Biologicals Private Ltd, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. This facility is one of India's few integrated sites for ADC Drug Substance production, designed to meet global regulatory standards. Leveraging Shilpa's 25-year expertise in highly potent compounds, this expansion strategically positions the company as a key Contract Development and Manufacturing Organization (CDMO) partner for global biotech and pharmaceutical companies in the high-value oncology segment.